Health & Biotech
An Australian life science company that is the exclusive wholesale distributor for the EAORON branded skin care range to pharmacies, supermarkets and specialist retailers in Australia and New Zealand and owns, produces, designs and distributes its own range of consumer health products under the EZZ brand.
The Company has two distinct and synergistic business models: a wholesale distribution model for the EAORON branded products in the skin care segment; and an integrated model including development, production and distribution for the EZZ branded products in the consumer health segment. Synergy is created by selling the EZZ branded products to established distribution channels previously developed from selling the EAORON branded products
EZZ Life Science formulate, produce, market and distribute health supplements under the brand of EZZ, with a focus on products with significant demand from the market by consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Did the earth move for you? The world shifts on its axis as it enters the Trump era mark two
Stockhead TV
Road to 2025: EZZ on a mission to advance quality of life and health
Health & Biotech
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Health & Biotech
ASX health stocks riding China’s two-way silk road for wellness at import expo
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
ASX Quarterly Health Wrap: Regulatory wins and record revenue
Health & Biotech
September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Health & Biotech
ASX health stocks capitalise on growing Southeast Asian market
Health & Biotech
EZZ serves up three-year Australian Open sponsorship deal
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
News
Closing Bell: CPI reading shifts rate cut outlook; Tabcorp plunges 15pc while Felix Gold soars
Health & Biotech
EZZ lifts on record revenue of $66.4m in FY24
News
Closing Bell: ASX, Nikkei fight back; RBA refuses to budge on interest rates
Health & Biotech
ASX Health Stocks: Amplia sees new success in pancreatic cancer trial
News
Market Highlights: Not much spared on chopping block after another big selloff, Wall Street loses US$3.5 trillion
Health & Biotech
EZZ launches into ‘functional’ food market with four new products
Health & Biotech